{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T20:10:35Z","timestamp":1740341435657,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1997,6,1]],"date-time":"1997-06-01T00:00:00Z","timestamp":865123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[1997,6,1]],"date-time":"1997-06-01T00:00:00Z","timestamp":865123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[1997,6]]},"DOI":"10.1007\/bf03189794","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T00:52:59Z","timestamp":1280883179000},"page":"121-125","source":"Crossref","is-referenced-by-count":2,"title":["The effect of velnacrine on the mixed function oxidase system"],"prefix":"10.1007","volume":"22","author":[{"given":"M. J.","family":"Eccles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. C.","family":"Danbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J. C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03189794_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00697388","volume":"61","author":"T. Arendt","year":"1983","unstructured":"Arendt T., Bigl V., Arendt A., Tennstedt A. (1983): Loss of neurons in the nucleus basalis of Meynert in Alzheimer\u2019s disease, paralysis agitans and Korsakoff\u2019s disease. Acta Neuropathol., 61, 101\u2013108.","journal-title":"Acta Neuropathol."},{"key":"BF03189794_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0022-510X(83)90045-X","volume":"59","author":"J.M. Candy","year":"1983","unstructured":"Candy J.M., Perry E.K. (1983): Pathological changes in the nucleus of Meynert in Alzheimer\u2019s and Parkinson\u2019s diseases. J. Neurol. Sci., 59, 277\u2013289.","journal-title":"J. Neurol. Sci."},{"key":"BF03189794_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ana.410170210","volume":"17","author":"J.D. Rogers","year":"1985","unstructured":"Rogers J.D., Brogan D., Mirra S.S. (1985): The nucleus basalis of Meynert in neurological disease: A quantitative morphological study. Ann. Neurol., 17, 163\u2013170.","journal-title":"Ann. Neurol."},{"key":"BF03189794_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.7058341","volume":"215","author":"P.J. Whitehouse","year":"1986","unstructured":"Whitehouse P.J., Price D.L., Struble R.G. (1986): Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain. Science, 215, 1237\u20131239.","journal-title":"Science"},{"key":"BF03189794_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/ddr.430050108","volume":"5","author":"C.A. Johns","year":"1985","unstructured":"Johns C.A., Haroutunian V., Greenwald B.S. (1985): Development of cholinergic drugs for the treatment of Alzheimer\u2019s disease. Drug. Dev. Res., 5, 77\u201396.","journal-title":"Drug. Dev. Res."},{"key":"BF03189794_CR6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1749-6632.1991.tb00229.x","volume":"640","author":"F.M. Murphy","year":"1991","unstructured":"Murphy F.M., Hardiman S.T., Nash R.J., et al. (1991): Evaluation of HP029 (velnacrine maleate) in Alzheimer\u2019s disease. Ann. NY Acad. Sci., 640, 253\u2013262.","journal-title":"Ann. NY Acad. Sci."},{"key":"BF03189794_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/jama.271.13.985","volume":"271","author":"M.J. Knapp","year":"1994","unstructured":"Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. (1994): A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer\u2019s disease. JAMA, 271, 985\u2013991.","journal-title":"JAMA"},{"key":"BF03189794_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2125.1994.tb04316.x","volume":"38","author":"V. Spaldin","year":"1994","unstructured":"Spaldin V., Madden S., Pool W.F., Woolf T.F., Park B.K. (1994) The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol., 38, 15\u201322.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BF03189794_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0090-9556(25)07377-5","volume":"24","author":"J.E. Sharer","year":"1996","unstructured":"Sharer J.E., Wrighton S.A. (1996): Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab. Dispos., 24, 487\u2013494.","journal-title":"Drug Metab. Dispos."},{"key":"BF03189794_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2165\/00003088-198308050-00001","volume":"8","author":"D.D. Breimer","year":"1983","unstructured":"Breimer D.D. (1983): Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin. Pharmacokinet., 8, 371\u2013377.","journal-title":"Clin. Pharmacokinet."},{"key":"BF03189794_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3109\/00498259009046835","volume":"20","author":"A.R. Boobis","year":"1990","unstructured":"Boobis A.R., Sesardic D., Murray B.P., et al. (1990): Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica, 20, 1139\u20131161.","journal-title":"Xenobiotica"},{"key":"BF03189794_CR12","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/0024-3205(80)90629-3","volume":"26","author":"T. Inaba","year":"1980","unstructured":"Inaba T., Lucassen M., Kalow W. (1980): Antipyrine metabolism in the rat by three hepatic monooxygenases. Life. Sci., 26, 1977\u20131983.","journal-title":"Life. Sci."},{"key":"BF03189794_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3109\/00498258409151465","volume":"14","author":"J.C. Rhodes","year":"1984","unstructured":"Rhodes J.C., Hall S.T., Houston J.B. (1984): Inhibition of antipyrine metabolite formation in rats in vivo. Xenobiotica, 14, 677\u2013686.","journal-title":"Xenobiotica"},{"key":"BF03189794_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00003088-198207010-00002","volume":"7","author":"A. Somogyi","year":"1982","unstructured":"Somogyi A., Gugler R. (1982): Drug interactions with cimetidine. Clin. Pharmacokinet., 7, 23\u201341.","journal-title":"Clin. Pharmacokinet."},{"key":"BF03189794_CR15","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1016\/0006-2952(80)90448-7","volume":"29","author":"O. Pelkonen","year":"1980","unstructured":"Pelkonen O., Puurunen J. (1980): The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. Biochem. Pharmacol., 29, 3075\u20133080.","journal-title":"Biochem. Pharmacol."},{"key":"BF03189794_CR16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0016-5085(82)90127-5","volume":"82","author":"R.G. Knodell","year":"1982","unstructured":"Knodell R.G., Holtzmann J.L., Crankshaw D.L. (1982): Drug metabolism by rat and human hepatic microsomes in response to interactions with histamine H2 antagonists. Gastroenterology, 82, 84\u201388.","journal-title":"Gastroenterology"},{"key":"BF03189794_CR17","first-page":"110","volume":"17","author":"E.M. Sorkin","year":"1983","unstructured":"Sorkin E.M., Darvey D.L. (1983): Review of cimetidine drug interactions. Drug Intell. Clin. Pharm., 17, 110\u2013120.","journal-title":"Drug Intell. Clin. Pharm."},{"key":"BF03189794_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00004836-198312001-00010","volume":"5","author":"J.R. Powell","year":"1983","unstructured":"Powell J.R., Donn K.H. (1983): The pharmacokinetic basis for histamine H2 antagonist drug interactions. Concepts and implications. J. Clin. Gastroenterol., 5, 95\u2013113.","journal-title":"J. Clin. Gastroenterol."},{"key":"BF03189794_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3109\/00498258409151428","volume":"14","author":"A. Bast","year":"1984","unstructured":"Bast A., Savenije-Chapel E.M., Kroes B.H. (1984): Inhibition of mono-oxygenase and oxidase activity of rat hepatic cytochrome P450 by histamine H2 blockers. Xenobiotica, 14, 399\u2013408.","journal-title":"Xenobiotica"},{"key":"BF03189794_CR20","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/0006-2952(85)90408-3","volume":"34","author":"J.C. Jensen","year":"1985","unstructured":"Jensen J.C., Gugler R. (1985): Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P450. Biochem. Pharmacol., 34, 2141\u20132146.","journal-title":"Biochem. Pharmacol."},{"key":"BF03189794_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0009-2797(88)90091-9","volume":"67","author":"E. Rekka","year":"1988","unstructured":"Rekka E., Sterk G.J., Timmerman H., Bast, A. (1988): Identification of structural characteristics of some potential histamine H2 antagonists that determine the interaction with rat hepatic P450. Chem. Biol. Interact., 67, 117\u2013127.","journal-title":"Chem. Biol. Interact."},{"key":"BF03189794_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/096032719301200209","volume":"12","author":"S.P. Faux","year":"1993","unstructured":"Faux S.P., Combes R.D. (1993): Interaction of cimetidine with cytochrome P450 and effect on mixed function oxidase activities of liver microsomes. Hum. Exp. Toxicol., 12, 147\u2013152.","journal-title":"Hum. Exp. Toxicol."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03189794.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF03189794\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03189794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03189794.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T19:31:51Z","timestamp":1740339111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF03189794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["BF03189794"],"URL":"https:\/\/doi.org\/10.1007\/bf03189794","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}